River Road Asset Management LLC lifted its stake in shares of Progyny, Inc. (NASDAQ:PGNY – Free Report) by 13.9% during the 4th quarter, HoldingsChannel.com reports. The firm owned 687,824 shares of the company’s stock after buying an additional 83,912 shares during the quarter. River Road Asset Management LLC’s holdings in Progyny were worth $17,663,000 as of its most recent SEC filing.
A number of other hedge funds have also bought and sold shares of the company. Caitong International Asset Management Co. Ltd bought a new stake in Progyny in the fourth quarter valued at about $25,000. Hantz Financial Services Inc. grew its position in shares of Progyny by 79.4% in the 4th quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company’s stock worth $43,000 after acquiring an additional 742 shares in the last quarter. Quarry LP grew its position in shares of Progyny by 2,004.1% in the 3rd quarter. Quarry LP now owns 3,598 shares of the company’s stock worth $77,000 after acquiring an additional 3,427 shares in the last quarter. Canada Pension Plan Investment Board bought a new stake in shares of Progyny in the 2nd quarter valued at approximately $77,000. Finally, New Age Alpha Advisors LLC bought a new stake in shares of Progyny in the 4th quarter valued at approximately $94,000. 94.93% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling at Progyny
In other Progyny news, CFO Mark S. Livingston sold 8,275 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $25.50, for a total transaction of $211,012.50. Following the completion of the transaction, the chief financial officer directly owned 79,063 shares of the company’s stock, valued at $2,016,106.50. The trade was a 9.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Cheryl Scott sold 7,439 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $26.39, for a total transaction of $196,315.21. Following the transaction, the director directly owned 19,772 shares of the company’s stock, valued at $521,783.08. The trade was a 27.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 36,916 shares of company stock valued at $939,875. Corporate insiders own 9.90% of the company’s stock.
Analyst Upgrades and Downgrades
Get Our Latest Research Report on Progyny
Progyny Price Performance
NASDAQ:PGNY opened at $26.08 on Friday. Progyny, Inc. has a 12-month low of $16.10 and a 12-month high of $28.75. The firm has a market capitalization of $2.04 billion, a P/E ratio of 33.87, a P/E/G ratio of 2.30 and a beta of 1.03. The business has a 50 day simple moving average of $22.42 and a 200 day simple moving average of $22.30.
Progyny (NASDAQ:PGNY – Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported $0.50 earnings per share for the quarter, topping the consensus estimate of $0.26 by $0.24. The firm had revenue of $328.50 million for the quarter, compared to analyst estimates of $326.46 million. Progyny had a return on equity of 13.34% and a net margin of 5.23%.The firm’s revenue for the quarter was down 26.4% on a year-over-year basis. During the same period last year, the company earned $0.17 earnings per share. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. Research analysts anticipate that Progyny, Inc. will post 1.07 EPS for the current fiscal year.
Progyny declared that its Board of Directors has initiated a stock buyback program on Tuesday, May 26th that allows the company to buyback $200.00 million in shares. This buyback authorization allows the company to repurchase up to 10.3% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s management believes its stock is undervalued.
Progyny Company Profile
Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.
The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.
Read More
- Five stocks we like better than Progyny
- Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself?
- Rackspace’s AI Land Grab: Plugging Into the Next Compute Boom
- Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore
- Why Kroger’s Pullback Could Be a Gift for Patient Investors
Want to see what other hedge funds are holding PGNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progyny, Inc. (NASDAQ:PGNY – Free Report).
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.
